# Relative Bioavailability and Food Effect Study of Losmapimod 15 mg Tablets

> **NCT05002231** · PHASE1 · COMPLETED · sponsor: **Fulcrum Therapeutics** · enrollment: 18 (actual)

## Conditions studied

- Healthy Adult Subjects

## Interventions

- **DRUG:** Losmapimod 15 mg oral tablet
- **DRUG:** Losmapimod two 7.5 mg oral tablets
- **DRUG:** Losmapimod one 15 mg oral tablet

## Key facts

- **NCT ID:** NCT05002231
- **Lead sponsor:** Fulcrum Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-19
- **Primary completion:** 2021-10-05
- **Final completion:** 2021-10-22
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2021-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05002231

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05002231, "Relative Bioavailability and Food Effect Study of Losmapimod 15 mg Tablets". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05002231. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*